

Regional Workshop on Patent Examination Quality Management

Session 6

Quality Management at the International Arena and Approach to Substantive Patent Examination

Tokyo, Japan June 21 and 23, 2017

Mr. Ken-Ichiro NATSUME
Director
PCT International Cooperation Division


What is "Quality" in Patent Examination?

- No oppositions / invalidations after grant/publication
 - → Strong patent (stable patent right)
- Meet the patentability request
 - Novelty, Inventive Step, Industrial Applicability
 - other requirements according to each jurisdiction (software related inventions)
- Balance between applicants and other parties
- Clear scope of the claims
- Validity / Reliability (transparency, consistency, efficiency)
- Citation
- Time factor (the earlier, the better?)
- Communication with stakeholders
- Satisfaction of customer



Quality Management System

- Quality Control
- Management
 - Planning
 - Assurance
 - □ Control
 - Improvement






Quality Management in the PCT System

PCT INTERNATIONAL SEARCH AND
PRELIMINARY EXAMINATION GUIDELINES

Chapter 21

Common Quality Framework for International Search and Preliminary Examination





PCT Quality Framework

- 1. Leadership and policy
- 2. Resources
- 3. Management of administrative workload
- 4. Quality assurance
- 5. Communication
- 6. Documentation
- 7. Search process documentation
- 8. Internal review
- 9. Reporting arrangements



Cooperation (Work sharing)

- Collaboration
- Cooperation
- Work sharing









PCT/MIA Quality Subgroup

- Reports on QMS under Chapter 21 of the PCT Search and Examination Guidelines
- Sharing of Quality Policies and Guidelines
- Collecting User Feedback
- Feedback and Analysis on ISR and WO
- Quality Metrics
- Utilization of Search Results/Search Strategies of other Offices





Characteristics of International Search Reports

- % of PCT Search Reports (SR) with at least one X, Y or E citation
- % of PCT SR with A citation only
- % of PCT SR with P and X
- % of PCT SR with Y and without X
- Average number of citations per SR
- Average number of NPL citations per SR
- % of patent citations in non-official languages ...




WIPO IP Statistics Data Center





Better Understanding of the Work of Other Offices

- Publication of Data Related to Search Strategies
- Standardized Clauses



Search Strategy available on **PATENTSCOPE**

| | | Search | Inform | ation S | Staten | nent (S | SIS) | |
|-------------------------------------|------------------------|-----------------------|-------------|--|---------|---------------------|----------|----------------|
| Australian Government IP Australia | | Application Number | | PCT/IB2010/001723 | | | 1 | |
| | | A | . Search De | tails | | | - | |
| Additional Members | | and the second | | Earlier Search Results (if available) | | F N 33 2 | | |
| of the Search Team if convened): | R. Perera, B. Mitrovic | | Curre | Current SIS Completion Date | | 21 November 2012 | | |
| | | В. | Search Stra | itegy | | TAYOO CO | | |
| 1.4 | | | 774 | | | | | - 0 |
| Databases : WPI, E | PODOC | . 9 1 | | | | | | |
| | a | | | | | | | |
| SS Results | | | | | | | | |
| | NNECTOR? | | | | 14 | | | |
| 2 868661LI | | | | | | | | |
| | | E? OR CONDU | CTOR? | | | | | |
| 4 209289LI | | | | | | | | |
| | ELD+ OR SCR | REEN+ | | | | | | |
| 6 14421LI | | | | | | nere i romane euspe | | r appearances. |
| | | ND+, INNER, (| OUTER, LO | OWER, U | PPER, C | THER, A | NOTHER | , TWO, |
| TWIN, PAIR, DOU | | | | | | | | |
| 8 2597 75W | | | | | | | | |
| | | ASING?, ENC | LOSUR+, | SHELL?, | ENCAS | +, SHRO | UD+, COV | ER+ |
| 10 2181 75V | | | | | | | | |
| 11 803 8 AN | The second second | | | | | | | |
| | TED W CIRC | | | | | | (4) | |
| | | INTED) D BOA | ARD? | 9 | | | | |
| | 12, 13, PCB? | | | | | | | |
| 15 87 11 A | | | | | | | 92.00 | |
| | TAL+ OR ALL | JMIN+ | | 7967 | | | 9.8 | |
| | DUCTIVE | | | | | | | |
| 18 5878 16 C | | er compto | | - 2 | | | | |
| | ULAT+ OR DI | ELECTRIC+ | 20 | | | | | |
| 20 1152 7 5V | 10000 | 200 | 2 | | | | 7 | |
| 21 1251 75V | | 0.00.01) 43.75 | ora. | | | | | |
| 22 145 (80 | K 20) AND (10 | 0 OR 21) AND | 14 | | | | | |
| 22 420 / 0.0 | D 20) AND 14 | | | | | | | |
| 23 428 (80 | R 20) AND 14 | | | | | | | |
| | | | | | 1 7 | | | |
| | | | | | | 8 6 | | |
| | | | | | | | | |

Search History:

Limited Classification Search

The Patent Analyst performed a limited classification search within the following US, IPC, ECLA, or F-Term classification areas:

U.S. Class/Subclass(es): 435/4, 5, 6.1, 6.12, 6.15, 7.2, 7.32, 29, 34, 69, 1, 69, 7, 71, 1, 91, 1, 91, 2, 91.32, 91.33, 91.4, 471, 472, 476, 477, 478

IPC (8) Class/Subclass(es): C12N 7/00, 7/01, 7/02, 15/00, 15/09, 15/10, 15/33, 15/34, 15/52, 15/63, 15/66, 15/76; C12Q 1/68, 1/70 (2012.01)

See Global Search Results.

Global Patent Literature Text Search

The Patent Analyst performed the following global text search, which was not limited by classification but may or may not have been limited by other criteria:

PATBASE

| # | Search query | Results |
|----|---|-------------------------|
| 1 | (PA=("SEQUELLA" OR "SEQUELLA_INC" OR "SEQUELLA_INCORPORATED")) | 11 |
| 2 | (INV=("MULVEY_MATTHEW" OR "MULVEY_MATTHEW_C")) | 3 |
| 3 | (INV=("EINCK_LEO" OR "EINCK_LEO_MCLEAN_VA_22101_US" OR "EINCK_LEO_US")) | 6 |
| 4 | (INV=("SACKSTEDER_KATHERINE")) | 2 |
| 5 | 2 AND 3 AND 4 | 2 |
| 6 | PN=WO2006/075996 | 1 |
| 7 | PN=WO97/22713 | 1 |
| 8 | PN=WO99/16868 | 1 |
| 9 | PN=US6300061 | 1 |
| 10 | PN=WO93/16172 | 1 |
| 11 | PN=WO94/25572 | 1 |
| 12 | (surrogate marker locus) | 2 |
| 13 | (mycobacterium tuberculosis) OR tuberculosis | 28537 |
| 14 | detect~ OR diagnose~ | more than 100,000 |
| 15 | viable~ | more than 100,000 |
| 16 | (virulence) OR efficacy | more than 100,000 |
| 17 | (bacteriophage) OR phage | 75720 |

Practical Approach for Better Quality

- Different size of the Office (could be different approach)
 - ■1000 examiners or 10 examiners (for the whole technological fields)
 - □Examination by its own examiners, outsourcing, temporary examiners ...

- Utilization of the results from other Offices
 - ■Wait for such results?



Discussions continue ...

■ What would be the best practice for your office?

It's your turn to think and act.

